Breaking News Instant updates and real-time market news.

LXRX

Lexicon

$12.81

0.44 (3.56%)

, IPSEY

Ipsen

$33.04

-0.36 (-1.08%)

12:37
09/19/17
09/19
12:37
09/19/17
12:37

Lexicon announces European Commission approves Xermelo

Lexicon Pharmaceuticals (LXRX) announced that the European Commission has approved Xermelo 250 mg as a first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults inadequately controlled by SSA therapy. This approval allows for the marketing of Xermelo by Lexicon's collaborator, Ipsen (IPSEY), in the above indication in all 28 member states of the European Union, Norway and Iceland, the company stated.

LXRX

Lexicon

$12.81

0.44 (3.56%)

IPSEY

Ipsen

$33.04

-0.36 (-1.08%)

  • 25

    Sep

LXRX Lexicon
$12.81

0.44 (3.56%)

03/01/17
WEDB
03/01/17
NO CHANGE
WEDB
Lexicon price target raised to $38 from $33 at Wedbush
Wedbush analyst Liana Moussatos increased her price target on Lexicon after the FDA approved Lexicon's lead drug, Zermelo, for carcinoid syndrome. The analyst thinks that the company has several additional upcoming positive potential catalysts. She keeps an Outperform rating on the stock.
03/07/17
SBSH
03/07/17
NO CHANGE
Target $28
SBSH
Buy
Lexicon price target raised to $28 from $24 at Citi
Citi analyst Yigal Nochomovitz raised his price target for Lexicon Pharmaceuticals to $28 saying the company's potential in diabetes remains underappreciated. Management's commentary on sotagliflozin should re-assure investors who remain unconvinced about the T1D thesis, Nochomovitz tells investors in a post-earnings research note. He keeps a Buy rating on Lexicon.
09/13/17
JPMS
09/13/17
NO CHANGE
JPMS
Neutral
Editorial published with Lexicon data reads cautiously, says JPMorgan
JPMorgan analyst Jessica Fye noted that full results for Lexicon Pharmaceuticals' Phase 3 inTandem3 study were released in the New England Journal of Medicine, accompanied by an editorial that reads cautiously on associated diabetic ketoacidosis. The comments from the editorial give her further pause on overall DKA risk and she thinks the relative risk in pumps patients may be at a threshold where physicians and the FDA could be cautious, she tells investors. Fye keeps a Neutral rating on Lexicon shares, which have fallen by more than 9% following the publication.
09/15/17
SBSH
09/15/17
NO CHANGE
Target $28
SBSH
Buy
Lexicon sold off on increased competition concerns, says Citi
Citi analyst Yigal Nochomovitz attributes the 10% selloff yesterday in shares of Lexicon Pharmaceuticals to increased competition after the 24-week results from the Depict1 trial for dapagliflozin in type 1 diabetes were presented. The data are broadly in line with what we've seen from sotagliflozin, suggesting a similar efficacy and safety profile between the two drugs, Nochomovitz tells investors in a research note. He reminds investors that he always expected competition in the adjunctive type 1 diabetes space, and currently models 35% peak share for sotagliflozin, which he thinks leaves "plenty of room for another SGLT inhibitor." The analyst has a Buy rating on Lexicon with a $35 price target.
IPSEY Ipsen
$33.04

-0.36 (-1.08%)

09/19/17
SOCG
09/19/17
UPGRADE
SOCG
Buy
Ipsen upgraded to Buy from Hold at Societe Generale
Societe Generale analyst Delphine Le Louet upgraded Ipsen to Buy with a price target of EUR 126.

TODAY'S FREE FLY STORIES

02:40
12/12/17
12/12
02:40
12/12/17
02:40
General news
FX Update: Narrow ranges have prevailed »

FX Update: Narrow ranges…

01:55
12/12/17
12/12
01:55
12/12/17
01:55
General news
FX Action: USD-JPY has plied a narrow 14 pip range »

FX Action: USD-JPY has…

NAV

Navistar

$40.07

0.17 (0.43%)

20:13
12/11/17
12/11
20:13
12/11/17
20:13
Upgrade
Navistar rating change at Stifel »

Navistar upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

GBT

Global Blood Therapeutics

$44.78

-0.925 (-2.02%)

20:10
12/11/17
12/11
20:10
12/11/17
20:10
Conference/Events
Global Blood Therapeutics to hold an investor webcast »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

VMW

VMware

$121.09

1.52 (1.27%)

19:55
12/11/17
12/11
19:55
12/11/17
19:55
Conference/Events
VMware management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 17

    Jan

MMC

Marsh & McLennan

$83.93

-0.2 (-0.24%)

19:52
12/11/17
12/11
19:52
12/11/17
19:52
Conference/Events
Marsh & McLennan management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

BG

Bunge

$69.67

-0.12 (-0.17%)

19:48
12/11/17
12/11
19:48
12/11/17
19:48
Conference/Events
Bunge management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

COP

ConocoPhillips

$51.69

0.12 (0.23%)

19:42
12/11/17
12/11
19:42
12/11/17
19:42
Conference/Events
ConocoPhillips management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

BL

BlackLine

$35.04

0.37 (1.07%)

19:36
12/11/17
12/11
19:36
12/11/17
19:36
Conference/Events
BlackLine management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 26

    Feb

AGIO

Agios Pharmaceuticals

$61.42

0.45 (0.74%)

19:25
12/11/17
12/11
19:25
12/11/17
19:25
Conference/Events
Agios Pharmaceuticals to hold an investor meeting »

Investor Meeting where…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

SGEN

Seattle Genetics

$55.27

-3.995 (-6.74%)

19:25
12/11/17
12/11
19:25
12/11/17
19:25
Conference/Events
Seattle Genetics to hold an investor and analyst event »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 16

    Dec

TCBK

TriCo Bancshares

$41.34

-0.3 (-0.72%)

19:15
12/11/17
12/11
19:15
12/11/17
19:15
Hot Stocks
TriCo to acquire FNB in transaction valued at roughly $315.3M »

TriCo Bancshares and FNB…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APLP

Archrock Partners LP

$11.41

0.19 (1.69%)

18:53
12/11/17
12/11
18:53
12/11/17
18:53
Hot Stocks
Archrock Partners LP names Raymond Guba interim CFO of general partner »

Archrock Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AROC

Archrock

$9.80

0.3 (3.16%)

, APLP

Archrock Partners LP

$11.41

0.19 (1.69%)

18:49
12/11/17
12/11
18:49
12/11/17
18:49
Hot Stocks
Archrock names Raymond Guba Interim CFO »

Archrock announced that…

AROC

Archrock

$9.80

0.3 (3.16%)

APLP

Archrock Partners LP

$11.41

0.19 (1.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAV

Advantage Oil & Gas

$4.05

0.05 (1.25%)

18:33
12/11/17
12/11
18:33
12/11/17
18:33
Hot Stocks
Advantage Oil & Gas announces 2018 capital budget of $175M »

Advantage Oil & Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OJSCY

Rosneft

18:22
12/11/17
12/11
18:22
12/11/17
18:22
Upgrade
Rosneft rating change at Goldman Sachs »

Rosneft upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GKOS

Glaukos

$24.85

-1.11 (-4.28%)

18:18
12/11/17
12/11
18:18
12/11/17
18:18
Recommendations
Glaukos analyst commentary at Piper Jaffray »

Piper sees 'another…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FATE

Fate Therapeutics

$4.14

-0.03 (-0.72%)

18:18
12/11/17
12/11
18:18
12/11/17
18:18
Hot Stocks
Fate Therapeutics reports Day 100 results from Phase 1 stage of PROTECT trial »

Fate Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

GM

General Motors

$41.67

-0.35 (-0.83%)

18:14
12/11/17
12/11
18:14
12/11/17
18:14
Periodicals
GM CEO: Cutting EV tax credit 'will have an impact' on sales, Reuters says »

General Motors CEO Mary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 16

    Jan

EDIT

Editas Medicine

$23.60

-1.36 (-5.45%)

18:02
12/11/17
12/11
18:02
12/11/17
18:02
Hot Stocks
Editas Medicine reports results from expanded CRISPR genome editing strategies »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMBH

First Mid-Illinois Bancshares

$39.09

0.42 (1.09%)

18:00
12/11/17
12/11
18:00
12/11/17
18:00
Hot Stocks
First Mid-Illinois Bancshares to acquire First BancTrust Corp for $73.8M »

First Mid-Illinois…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$120.42

0.5 (0.42%)

17:46
12/11/17
12/11
17:46
12/11/17
17:46
Initiation
Chevron initiated  »

Chevron initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPOR

Gulfport Energy

$13.13

0.67 (5.38%)

17:44
12/11/17
12/11
17:44
12/11/17
17:44
Initiation
Gulfport Energy initiated at Credit Suisse »

Gulfport Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQT

EQT Corporation

$57.13

0.75 (1.33%)

17:43
12/11/17
12/11
17:43
12/11/17
17:43
Initiation
EQT Corporation initiated at Credit Suisse »

EQT Corporation initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTC

Bitcoin

, BITCOIN

Bitcoin

17:43
12/11/17
12/11
17:43
12/11/17
17:43
Hot Stocks
SEC Chairman says no initial coin offerings have been registered »

Securities and Exchange…

BTC

Bitcoin

BITCOIN

Bitcoin

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.